Related Experiment Video For TROP2 antibody-drug conjugate
Updated: Jan 17, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?
Qing Zhao1, Xiao Luo1, Hua Xing1
1Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People's Republic of China.
Abstract:
Epithelial-myoepithelial carcinoma (EMC) of the breast is a rare biphasic tumor composed of intermixed malignant epithelial and myoepithelial components. Breast epithelial myoepithelial carcinoma lacks therapeutic strategies due to its rarity, and currently local treatment is still the main treatment. Herein we report an epithelial-myoepithelial carcinoma of the breast in a 33-year-old woman undergoing breast conserving surgery, sentinel lymph node biopsy, adjuvant chemotherapy and radiotherapy, with rapid liver and lung metastasis. After radiofrequency ablation therapy for metastatic lesions, vinorelbine plus cisplatin and TROP2 antibody-drug conjugate (ADC) treatment were given successively. After a brief improvement, drug resistance developed and the disease progressed. The patient died with the PFS 5.6 months.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Treatment Resistant Cancers
Mitogens and the Cell Cycle

